IPA: Inhibition of platelet aggregation; iv.: Intravenous. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or ...

Dr. Woulfe's research interests focus primarily on the intracellular signaling mechanisms of platelet activation and how signaling in platelets contributes to thrombosis in vivo. Agonists that extend ...

It will be important to establish whether the use of TPO-R agonists in combination with agents that minimize platelet removal, such as the monoclonal antibody to CD20, rituximab, will provide ...

Areas of expertise Platelets are the smallest cellular component of the blood and are an essential element in the primary haemostatic system. They are able to respond to a wide range of agonists and ...

Platelets play an important role in atherothrombotic disease. The currently available antiplatelet drugs target key steps of platelet activation including thromboxane A 2 synthesis, ADP-mediated ...